Suppr超能文献

肝移植后原发性胆汁性肝硬化复发的组织学证据。

Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation.

作者信息

Balan V, Batts K P, Porayko M K, Krom R A, Ludwig J, Wiesner R H

机构信息

Liver Transplant Unit, Mayo Clinic, Rochester, Minnesota.

出版信息

Hepatology. 1993 Dec;18(6):1392-8.

PMID:8244263
Abstract

Whether primary biliary cirrhosis recurs after orthotopic liver transplantation remains a controversial issue. Sixty consecutive patients with primary biliary cirrhosis with at least 1 yr of follow-up after liver transplantation were studied. All patients were treated with triple-drug immunosuppression (cyclosporine, prednisone, azathioprine). Hepatic biochemical parameters and protocol liver biopsy specimens were evaluated 1 wk, 3 wk, 4 mo and yearly after orthotopic liver transplantation and at times of liver dysfunction. Antimitochondrial antibody titers and IgM levels were determined at 4 mo and yearly. At the time of last follow-up, all patients had marked symptomatic improvement compared with their pretransplant condition, and 91% of the patients had normal hepatic biochemical parameters, including serum levels of alkaline phosphatase, bilirubin, ALT and IgM. In addition, all patients had significant decreases in antimitochondrial antibody titer (p = 0.0001) and significant decreases in serum levels of IgM (p = 0.0001). Forty-one of the 60 patients had near-normal liver histological appearance. Of those with abnormal histological appearance, five patients, 2 to 6 yr after orthotopic liver transplantation, had histological features typical of a florid duct lesion, suggesting recurrent primary biliary cirrhosis. All five patients with portal granulomas had normal hepatic biochemical values and were clinically asymptomatic. Two of the five patients had persistent antimitochondrial antibody titers. We consider the documented histological changes highly suggestive of recurrence of primary biliary cirrhosis after liver transplantation but, so far, have no evidence that the condition in these patients is progressive.

摘要

原位肝移植后原发性胆汁性肝硬化是否复发仍是一个有争议的问题。对连续60例原发性胆汁性肝硬化患者进行了研究,这些患者在肝移植后至少随访了1年。所有患者均接受三联免疫抑制治疗(环孢素、泼尼松、硫唑嘌呤)。在原位肝移植后1周、3周、4个月及每年以及出现肝功能障碍时,评估肝脏生化参数和常规肝活检标本。在4个月及每年测定抗线粒体抗体滴度和IgM水平。在最后一次随访时,与移植前相比,所有患者的症状均有明显改善,91%的患者肝脏生化参数正常,包括碱性磷酸酶、胆红素、谷丙转氨酶和IgM的血清水平。此外,所有患者的抗线粒体抗体滴度均显著降低(p = 0.0001),血清IgM水平也显著降低(p = 0.0001)。60例患者中有41例肝脏组织学表现接近正常。在组织学表现异常的患者中,5例在原位肝移植后2至6年出现典型的小胆管病变组织学特征,提示原发性胆汁性肝硬化复发。所有5例有门脉性肉芽肿的患者肝脏生化值正常,临床无症状。5例患者中有2例抗线粒体抗体滴度持续存在。我们认为所记录的组织学变化高度提示肝移植后原发性胆汁性肝硬化复发,但迄今为止,尚无证据表明这些患者的病情呈进行性发展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验